A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2001
10/17/2001	EP1144648A1 Cyclic nucleotide-associated proteins
10/17/2001	EP1144634A2 Novel complex-forming proteins
10/17/2001	EP1144633A1 Polypeptide
10/17/2001	EP1144632A2 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
10/17/2001	EP1144630A2 Human cell signaling proteins (csig)
10/17/2001	EP1144627A2 Proteins capable of triggering g2/m transition and of interacting with cdc2- and cyclin b
10/17/2001	EP1144625A2 Nucleic-acid binding proteins
10/17/2001	EP1144623A1 Method and medicament for inhibiting the expression of a defined gene
10/17/2001	EP1144618A1 Method for isolating apoptosis-inducing dna sequences and detection system
10/17/2001	EP1144617A2 Cancer-associated proteins
10/17/2001	EP1144614A2 33 human secreted proteins
10/17/2001	EP1144605A2 Dimethylarginine dimethylaminohydrolases
10/17/2001	EP1144604A1 Cyclic peptide ligands that target urokinase plasminogen activator receptor, their pharmaceutical compositions and use
10/17/2001	EP1144598A2 Human homologues of proteins regulated by circadian rhythms
10/17/2001	EP1144454A2 Modified peptides as therapeutic agents
10/17/2001	EP1144451A2 Method of modulating cell differentiation or neoplastic trnasformation by altering cadherin-11 expression or function
10/17/2001	EP1144443A2 Human membrane transport proteins
10/17/2001	EP1144441A2 Disintegrin homologs
10/17/2001	EP1144439A2 Hematopoietic regulatory factors and methods of use thereof
10/17/2001	EP1144435A2 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144431A2 16-hydroxyestratrienes as selective estrogens
10/17/2001	EP1144426A2 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
10/17/2001	EP1144423A1 Bis-terpyridine-platinum(ii) complexes
10/17/2001	EP1144421A1 Phosphinic pseudopeptides inhibitors of matrix metalloproteases
10/17/2001	EP1144414A2 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
10/17/2001	EP1144412A1 Immunosuppressive effects of pteridine derivatives
10/17/2001	EP1144409A2 Phenyl urea and phenyl thiourea derivatives
10/17/2001	EP1144396A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
10/17/2001	EP1144394A1 1-heterocycle substituted diarylamines
10/17/2001	EP1144390A2 Kinase inhibitors
10/17/2001	EP1144388A1 Acyl derivatives which treat vla-4 related disorders
10/17/2001	EP1144387A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
10/17/2001	EP1144385A1 Benzoheterocycles and their use as mek inhibitors
10/17/2001	EP1144384A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144372A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
10/17/2001	EP1144371A1 Benzenesulphonamide derivatives and their use as mek inhibitors
10/17/2001	EP1144370A2 Thyroid receptor ligands
10/17/2001	EP1144369A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/17/2001	EP1144362A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
10/17/2001	EP1144348A2 Lta 4? hydrolase inhibitors
10/17/2001	EP1144012A1 Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery
10/17/2001	EP1144011A2 Prodrug compounds and process for preparation thereof
10/17/2001	EP1144004A1 Her-2 binding antagonists
10/17/2001	EP1144003A1 Methods and devices for delivery of agents to breast milk ducts
10/17/2001	EP1143985A2 Use of lactobacillus salivarius
10/17/2001	EP1143982A2 Method for preparing membrane vesicles
10/17/2001	EP1143981A1 Treatment and prevention of hiv and other viral infections
10/17/2001	EP1143975A1 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances
10/17/2001	EP1143970A1 Pyridine compounds, use and preparation thereof
10/17/2001	EP1143968A2 Composition and methods for administration of water-insoluble paclitaxel derivatives
10/17/2001	EP1143965A1 Carbocyclic potassium channel inhibitors
10/17/2001	EP1143961A2 Regulators of the ptc or smoothened pathway, compositions and uses related thereto
10/17/2001	EP1143960A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
10/17/2001	EP1143949A2 19-nor-vitamin d3 compounds with calcemic activity
10/17/2001	EP1143946A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
10/17/2001	EP1143944A2 Use of arylalkanoylpyridazines
10/17/2001	EP1143943A2 P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant
10/17/2001	EP1143933A2 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
10/17/2001	EP1143932A1 Transnasal transport/immunisation with highly adaptable carriers
10/17/2001	EP1143920A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system
10/17/2001	EP1143796A1 Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
10/17/2001	EP1064291A4 Methods of synthesizing gm3
10/17/2001	EP0842185B1 Ara-c derivatives
10/17/2001	EP0754682B1 Aminostilbazole derivative and medicine
10/17/2001	EP0652871B1 Benzodiazepine derivatives
10/17/2001	CN1318059A Isoquinolines as urokinase inhibitors
10/17/2001	CN1318058A 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as CRTP inhibitors
10/17/2001	CN1318054A Novel compounds
10/17/2001	CN1317952A Improved method for targeted topial treatment of disease
10/17/2001	CN1317495A Ocean thalassiomycete hypoxylon polyose and its extracting process and application
10/17/2001	CN1317484A Fullerene derivative of E-isomer
10/17/2001	CN1073158C Anti-egfr single-chain Fvs and anti-egfr antibodies
10/17/2001	CN1073108C Texane derivatives having pyridil substituted C13 side chain, their prepn. and their use as anti-tumor agents
10/17/2001	CN1073106C Taxoids compound, preparation thereof, and pharmaceutical compsns. contg. same
10/17/2001	CN1073105C Semi-synthetic taxanes with anti-tumoural activity
10/17/2001	CN1072942C Oral liquid for inhibitting cancer and prepn. method thereof
10/17/2001	CN1072940C Oral liquid for anti-cancer and its prepn. method
10/17/2001	CN1072938C Traditional chinese medicine for curing gastric disease
10/17/2001	CN1072908C Food additive benefiting patients of diabetics, coronary heart disease and tumor
10/16/2001	US6303793 Intermediates for cyclin-dependent kinase inhibitors
10/16/2001	US6303774 Antiviral agents, anticancer agents, metabolic moderators
10/16/2001	US6303755 Therapeutic multispecific compounds comprised of anti-FCA receptor antibodies
10/16/2001	US6303660 Enhanced anti-cancer agent delivery to solid tumors by primer compounds
10/16/2001	US6303654 Exposing tumor cells to farnesyl anthranilate and carrier to inhibit or reduce tumor cell growth
10/16/2001	US6303653 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
10/16/2001	US6303641 Cyanoamidines as cell proliferation inhibitors
10/16/2001	US6303636 Arylsulfonylamino hydroxamic acid derivatives
10/16/2001	US6303634 Therapy and prophylaxis of breast cancer in a human by administering to human benzothiophene derivative
10/16/2001	US6303618 Cyclin dependent kinase inhibiting purine derivatives
10/16/2001	US6303604 Pharmaceutical composition comprising 2,4-diamino-6-benzyloxy-s-triazine and inactivation of O6-alkylguanine-DNA-alkyltransferase
10/16/2001	US6303601 Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
10/16/2001	US6303600 Substituted azabicyclic compounds
10/16/2001	US6303576 Contacting cell with modulating agent that comprises internalization moiety and compound having amino acid sequencel peptide analogue or peptidomimetic of compound which retains ablity to inhibit beta-catenin mediated response
10/16/2001	US6303376 Stimulation using cellular dna synthesis or repair mechanisms
10/16/2001	US6303342 Recombinant methods and materials for producing epothilones C and D
10/16/2001	US6303333 Expression vector which codes polypeptides for the diagnosis and treatment of cancer, dietetics, inflammation, cardiovascular disorders, crohn's diseases, neuropathies and immune defects
10/16/2001	US6303331 Vertebrate apoptosis gene: compositions and methods
10/16/2001	US6303312 Modifying cell phenotype; medical research and therapy
10/16/2001	US6303151 Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
10/16/2001	US6303123 Which bind and neutralize the hormone gnrh in vivo.

1 ... 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 ... 2211